GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review - Top-Institutions - MDSpire

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

  • By

  • Paula Rodriguez-Otero

  • Niels W. C. J. van de Donk

  • Kodandaram Pillarisetti

  • Ingrid Cornax

  • Deeksha Vishwamitra

  • Kathleen Gray

  • Brandi Hilder

  • Jaszianne Tolbert

  • Thomas Renaud

  • Tara Masterson

  • Christoph Heuck

  • Colleen Kane

  • Raluca Verona

  • Philippe Moreau

  • Nizar Bahlis

  • Ajai Chari

  • February 2, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Cell Therapy

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

Original Source(s)

GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

  • by Paula Rodriguez-Otero, Niels W. C. J. van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Philippe Moreau, Nizar Bahlis, Ajai Chari

  • February 2, 2024

Related Content

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma